Cargando…

Risk of Thromboembolic Events and Major Adverse Cardiovascular Events Following Antivascular Endothelial Growth Factor Therapy in Patients with Colorectal Cancer

SIMPLE SUMMARY: We assessed whether anti-VEGF therapy increases the risk of thromboembolic events or major adverse cardiovascular events (MACEs) in patients with colorectal cancer based on real-world evidence. Patients with advanced colorectal cancer who had previously received anti-VEGF therapy did...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yen-Cheng, Yeh, Liang-Tsai, Yang, Shun-Fa, Chou, Ming-Chih, Huang, Jing-Yang, Yeh, Chao-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817700/ https://www.ncbi.nlm.nih.gov/pubmed/36612005 http://dx.doi.org/10.3390/cancers15010009

Ejemplares similares

Endothelial Dysfunction Is Associated With Major Adverse Cardiovascular Events in Peritoneal Dialysis Patients
por: Lee, Mi Jung, et al.
Publicado: (2014)

Excess Risk of Major Adverse Cardiovascular and Kidney Events after Acute Kidney Injury following Living Donor Liver Transplantation
por: Chan, Yi-Chia, et al.
Publicado: (2022)

Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus
por: Lin, Fang-Ju, et al.
Publicado: (2017)

Long‐Term Effects of Unprovoked Venous Thromboembolism on Mortality and Major Cardiovascular Events
por: Chang, Wei‐Ting, et al.
Publicado: (2017)

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
por: Chen, Zhihao, et al.
Publicado: (2018)

Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
por: Mal, Kheraj, et al.
Publicado: (2020)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events
por: Gaist, David, et al.
Publicado: (2022)

Comparison of HEAR and HEART Scores for Major Adverse Cardiovascular Events
por: Uyan, Umut
Publicado: (2023)

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
por: Shin, Hong-Joon, et al.
Publicado: (2023)

CHADS(2) Scores in the Prediction of Major Adverse Cardiovascular Events in Patients with Cushing's Syndrome
por: Wang, Yuh-Feng, et al.
Publicado: (2014)

Long‐Term Visit‐to‐Visit Glycemic Variability as a Predictor of Major Adverse Limb and Cardiovascular Events in Patients With Diabetes
por: Hsu, Jung‐Chi, et al.
Publicado: (2023)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
por: Peluso, Rosario, et al.
Publicado: (2018)

Deep Venous Thrombosis and Risk of Consequent Sepsis Event: A Retrospective Nationwide Population-Based Cohort Study
por: Yeh, Ying-Tung, et al.
Publicado: (2021)

Underestimated Ischemic Heart Disease in Major Adverse Cardiovascular Events after Septicemia Discharge
por: Hsiao, Chih-Chun, et al.
Publicado: (2022)

Major Adverse Cardiovascular Events after Treatment in Early-stage Breast Cancer Patients Receiving Hormone Therapy
por: Chou, Ying-Hsiang, et al.
Publicado: (2020)

Heterogeneous plaque–lumen geometry is associated with major adverse cardiovascular events
por: Gu, Sophie Z, et al.
Publicado: (2023)

Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
por: Armstrong, Ehrin J., et al.
Publicado: (2014)

Chemotherapy and adverse cardiovascular events in colorectal cancer patients undergoing surgical resection
por: Koo, Chieh Yang, et al.
Publicado: (2021)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Effect of Heart Rate on Major Adverse Cardiovascular Events in Hypertensive Patients with Different Ages and Genders
por: Xi, Yang, et al.
Publicado: (2021)

Association of Major Adverse Cardiac Events and Beta-Blockers in Patients with and without Atherosclerotic Cardiovascular Disease: Long-Term Follow-Up Results of the T-SPARCLE and T-PPARCLE Registry in Taiwan
por: Liu, Patrick Yan-Tyng, et al.
Publicado: (2023)

Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib
por: Lee, Shou‐Wu, et al.
Publicado: (2018)

Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database
por: Hasegawa, Shiori, et al.
Publicado: (2017)

CT-derived fractional flow reserve for prediction of major adverse cardiovascular events in diabetic patients
por: Lan, Ziting, et al.
Publicado: (2023)

Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
por: Zheng, Meifan, et al.
Publicado: (2020)

Genetic information improves the prediction of major adverse cardiovascular events in the GENEMACOR population
por: Mendonça, Maria Isabel, et al.
Publicado: (2021)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection
por: Jiang, Joy, et al.
Publicado: (2023)

Necroptosis Drives Major Adverse Cardiovascular Events During Severe COVID-19
por: Wiscovitch-Russo, Rosana, et al.
Publicado: (2023)

Major adverse cardiovascular events are associated with necroptosis during severe COVID-19
por: Wiscovitch-Russo, Rosana, et al.
Publicado: (2023)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

IMPACT OF VACCINATION ON MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG PATIENTS WITH COVID-19
por: Jiang, Joy, et al.
Publicado: (2023)

Ten-year predictors of major adverse cardiovascular events in patients without angina
por: Premsagar, Preesha, et al.
Publicado: (2023)

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Epicardial adipose tissue thickness is not associated with adverse cardiovascular events in patients undergoing haemodialysis
por: Chen, Ying-Chih, et al.
Publicado: (2020)

Association of NFKB1 gene rs28362491 mutation with the occurrence of major adverse cardiovascular events
por: Luo, Jun-Yi, et al.
Publicado: (2022)

Editorial Comment: Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy
por: Barros, Rodrigo de Castro
Publicado: (2023)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hu5996m33gtdhvk3259785m6a0